Accès à distance ? S'identifier sur le proxy UCLouvain
Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer.
Primary tabs
Document type | Article de périodique (Journal article) – Article de recherche |
---|---|
Access type | Accès restreint |
Publication date | 2013 |
Language | Anglais |
Journal information | "European Journal of Cancer" - Vol. 49, no.12, p. 2633-2642 (2013) |
Peer reviewed | yes |
Publisher | Pergamon ((United Kingdom) Kidlington) |
issn | 0959-8049 |
e-issn | 1879-0852 |
Publication status | Publié |
Affiliations |
UCL
- SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie UCL - (SLuc) Unité d'oncologie médicale |
MESH Subject | Adult ; Humans ; Male ; Middle Aged ; Nausea ; Neoplasm Metastasis ; Neutropenia ; Pancreatic Neoplasms ; Proteinuria ; Receptors, Vascular Endothelial Growth Factor ; Recombinant Fusion Proteins ; Aged ; Treatment Outcome ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols ; Deoxycytidine ; Disease-Free Survival ; Double-Blind Method ; Drug Administration Schedule ; Female |
Links |
Bibliographic reference | Rougier, Philippe ; Riess, Hanno ; Manges, Robert ; Karasek, Petr ; Humblet, Yves ; et. al. Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer.. In: European Journal of Cancer, Vol. 49, no.12, p. 2633-2642 (2013) |
---|---|
Permanent URL | http://hdl.handle.net/2078.1/156808 |